Wegovy: good or bad? An honest answer to a fair question

The biggest myth: Wegovy is a shortcut that works without any effort

This is where most of the 'bad' sentiment about Wegovy originates. People see dramatic weight-loss headlines, expect the medicine to do everything alone, and feel let down, or they see others losing confidence in a treatment that has, in fact, been tested rigorously. Wegovy is not a passive intervention. The licence requires it to be used alongside a reduced-calorie diet and increased physical activity. Remove those two elements and the results shrink considerably. The medicine works by acting on GLP-1 receptors in the brain and gut, reducing appetite and slowing how quickly food leaves the stomach, but the body still needs the right input to respond well.

The STEP 1 trial, published in the New England Journal of Medicine, randomised over 1,900 adults without diabetes to semaglutide 2.4mg or placebo. Average weight reduction in the semaglutide group was around 15% over 68 weeks, roughly three times the placebo effect. That is not a modest signal. But participants in both groups received lifestyle support, which is a central part of how the treatment is designed to be delivered. Think of Wegovy as amplifying the effort you are already making, not replacing it. That reframe matters enormously for setting realistic expectations.

For a fuller look at how good semaglutide is and what the clinical data shows, the semaglutide overview on this site covers the mechanism in plain terms.

Where Wegovy genuinely earns its 'good' reputation

Separate from the weight-loss numbers, there are a few things worth knowing about what the evidence base looks like. First, the magnitude of weight loss in the STEP programme was unlike anything seen in previous non-surgical interventions. For people living with obesity-related health conditions (high blood pressure, sleep apnoea, joint pain, elevated cholesterol) losing 10–15% of body weight can produce measurable improvements in those conditions, not just a change on the scales.

Second, NICE assessed the evidence and recommended semaglutide (Wegovy) for use in the NHS, albeit within specialist weight management services and for a maximum of two years. That recommendation did not happen because the regulator was easily impressed. NICE's appraisal of Wegovy (TA875) reviewed the full clinical programme before issuing that guidance. The treatment also now holds a UK licence for reducing the risk of major cardiovascular events in eligible adults, a benefit that sits well beyond the scales.

Third, a higher 7.2mg dose of semaglutide was approved by the MHRA in early 2026, with trial results of around 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide. If you want to understand whether Wegovy is genuinely good as a treatment option, that page covers the broader picture in more detail.

The side effects, honest, not alarming

Wegovy's main downsides are gastrointestinal. Nausea is the most commonly reported side effect, followed by diarrhoea, constipation, vomiting, reflux and indigestion. For many people these are worst in the first week or two after starting (or after a dose increase) and they settle. For some, they persist more than expected, and occasionally that leads someone to stop treatment. That is a real outcome and worth knowing about, and readers who are still weighing up whether Wegovy is any good will find a balanced breakdown of these trade-offs there.

The dosing schedule is designed partly to minimise this: treatment starts at a low tolerability dose and increases gradually over several months. The NHS patient information page for semaglutide lists all known side effects clearly and explains which require prompt medical attention.

Two safety points deserve specific mention. In January 2026 the MHRA issued a Drug Safety Update following a review of GLP-1 medicines: acute pancreatitis is a known but infrequent risk, and anyone who develops severe abdominal pain that radiates to the back (with or without vomiting) should get medical help that day, not wait. Separately, women taking oral contraceptives alongside tirzepatide (not semaglutide specifically, though the principle is worth knowing) may need an additional method during dose changes; our frequently asked questions address this for anyone mid-treatment. Any concerns about your own medication interactions belong with your prescriber.

One practical note on timing: if you are planning to start or resume treatment around a bank holiday, Christmas, or even just payday at the end of the month, it is worth factoring in that some weeks are easier than others for sticking to the lifestyle elements, and if you are unsure about storage during those periods, guidance on whether Wegovy goes bad explains what to do if a pen has been left out or exposed to heat. Side effects and appetite changes do not take holidays, and having support available matters. At nume, prescribers are reachable for aftercare seven days a week.

Who it suits, who should think carefully, and what decides

Wegovy is licensed for adults with a BMI of 30 or above, or from 27 with at least one weight-related condition such as high blood pressure, type 2 diabetes, obstructive sleep apnoea or elevated cholesterol. Lower BMI thresholds apply for people of some South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, in line with UK guidance. Those are the eligibility markers, but a prescriber still needs to assess the full picture. A number on a BMI calculator is not the same as clinical suitability.

Wegovy is not recommended during pregnancy, while breastfeeding, or for anyone actively trying to conceive. It is not licensed for under-18s. People with a personal or family history of medullary thyroid carcinoma, or with multiple endocrine neoplasia type 2, should not use it. Certain gastrointestinal conditions and a history of pancreatitis will also require careful prescriber review.

The cost context is part of the 'good or bad' question for many people. Wegovy is not available without a prescription, and private prescriptions currently sit in a market where prices vary considerably between providers. A fair comparison of what a private Wegovy prescription typically costs is on the Wegovy cost page. The short version: what is included in that price (or not) matters as much as the headline figure.

If you want a clinical view of whether Wegovy is right for your situation specifically, the place to start is a proper consultation. Our free consultation is reviewed by a GPhC-registered prescriber (a real clinician, not automated software) the same day you submit it.